Acumen Pharmaceuticals Inc (ABOS) Stock Price, Quote & News

Company Profile

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate Sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2, which has completed the INTERCEPT-AD phase 1 clinical trial and in ALTITUDE-AD phase 2 clinical trial to target soluble amyloid-beta oligomers. It has a collaboration and license agreement with Halozyme, Inc. for t...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 344 4190

Website: acumenpharm.com

Address:

1210-1220 Washington St., Suite 210, Newton, United States

mhaven2020 Dec. 5 at 7:18 PM

$ABOS thanks for the dip. Bought more.

0 · Reply

SannieVerraderlijk Dec. 5 at 9:56 AM

$ABOS This is a sleeper, trading at 20ish million EV, huge indication and good scientific rationale. Could see runup into eoy 26

0 · Reply

mhaven2020 Dec. 4 at 6:08 PM

$ABOS 15 minute chart. Looking for direction. Needs volume.

0 · Reply

mhaven2020 Dec. 4 at 5:24 PM

$ABOS shouldn't be too long before these tickers start hitting market mover status. $IOVA . The number of times occurring in my daily scans is over the last 6 weeks.

1 · Reply

mhaven2020 Dec. 4 at 3:55 PM

$ABOS Just dropped a video on these two little gems. $IOVA Follow me on YouTube and X as well for more info. https://youtu.be/BVha65Bwzog

0 · Reply

mhaven2020 Dec. 3 at 5:36 PM

$ABOS steady...

0 · Reply

mhaven2020 Dec. 3 at 5:15 PM

$ABOS Seems to be gearing up for a run.

0 · Reply

mhaven2020 Dec. 3 at 2:28 PM

$ABOS $IOVA getting notes together for a video for youtube.

0 · Reply

mhaven2020 Dec. 3 at 2:17 PM

$ABOS heavy here. Something is coming.

0 · Reply

mhaven2020 Nov. 26 at 2:58 PM

$SAVA closed this and most of thenother ones. Still holding a bit of $IOVA and $IVVD. Dropping into $ABOS and $IVP for a few days with the profits.

1 · Reply

Acumen Pharmaceuticals, Inc. (ABOS) Q3 2025 Earnings Call Transcript

Sep 2, 2025, 9:28 PM EDT - 3 months ago

Acumen Pharmaceuticals, Inc. (ABOS) Presents At Citi's Biopharma Back To School Conference Transcript

Aug 26, 2025, 4:00 PM EDT - 3 months ago

Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences

Aug 12, 2025, 2:46 PM EDT - 4 months ago

Acumen Pharmaceuticals, Inc. (ABOS) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 7:00 AM EDT - 4 months ago

Acumen Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Highlights

Aug 5, 2025, 4:00 PM EDT - 4 months ago

Acumen Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 12, 2025

Jul 15, 2025, 7:00 AM EDT - 5 months ago

JCR Pharmaceuticals and Acumen Pharmaceuticals Announce Collaboration to Develop Therapy for Alzheimer's Disease, Enabled by J-Brain Cargo® Technology Platform

Jul 10, 2025, 8:00 AM EDT - 5 months ago

Acumen Pharmaceuticals to Present Studies on Cost Savings Associated with Use of pTau217 Screening Assay in Phase 2 ALTITUDE-AD Study and Sabirnetug Oligomer-Selectivity at the Alzheimer's Association International Conference (AAIC®) 2025

May 13, 2025, 10:11 AM EDT - 7 months ago

Acumen Pharmaceuticals, Inc. (ABOS) Q1 2025 Earnings Call Transcript

May 7, 2025, 4:00 PM EDT - 7 months ago

Acumen Pharmaceuticals to Participate in the Bank of America Healthcare Conference

May 6, 2025, 4:00 PM EDT - 7 months ago

Acumen Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025

Apr 2, 2025, 7:00 AM EDT - 8 months ago

Acumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual Meeting

Mar 27, 2025, 10:05 AM EDT - 9 months ago

Acumen Pharmaceuticals, Inc. (ABOS) Q4 2024 Earnings Call Transcript

Mar 20, 2025, 4:00 PM EDT - 9 months ago

Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025

Mar 18, 2025, 8:48 AM EDT - 9 months ago

Acumen Pharmaceuticals CEO Discusses Novel Targeted Therapies for Alzheimer's

Mar 12, 2025, 8:00 AM EDT - 9 months ago

Acumen Pharmaceuticals to Present During International Conference on Alzheimer's and Parkinson's Diseases 2025 and American Academy of Neurology Annual Meeting

Nov 26, 2024, 4:00 PM EST - 1 year ago

Acumen Pharmaceuticals to Participate in the 7th Annual Evercore ISI HealthCONx Conference

Nov 12, 2024, 1:17 PM EST - 1 year ago

Acumen Pharmaceuticals, Inc. (ABOS) Q3 2024 Earnings Call Transcript

Nov 11, 2024, 4:00 PM EST - 1 year ago

Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference

Nov 6, 2024, 4:00 PM EST - 1 year ago

Acumen Pharmaceuticals to Participate in the UBS Global Healthcare Conference

Oct 31, 2024, 8:05 AM EDT - 1 year ago

Acumen Pharmaceuticals Presents Innovative Trial Screening Advancements Utilizing pTau217 Assay in Phase 2 Study of Sabirnetug for Early Alzheimer's Disease at the 17th Annual Clinical Trials on Alzheimer's Disease Conference

Oct 23, 2024, 8:00 AM EDT - 1 year ago

Acumen Pharmaceuticals to Deliver Late-Breaking Presentation at 17th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference

Oct 15, 2024, 8:00 AM EDT - 1 year ago

Lucy Therapeutics Appoints Kim Drapkin as Board Chair

LENZ

Sep 30, 2024, 4:00 PM EDT - 1 year ago

Acumen Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference

Sep 25, 2024, 4:00 PM EDT - 1 year ago

Acumen Pharmaceuticals to Host Virtual R&D Day on Oct. 2, 2024

Sep 3, 2024, 4:00 PM EDT - 1 year ago

Acumen Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investor Conference

Aug 13, 2024, 11:17 AM EDT - 1 year ago

Acumen Pharmaceuticals, Inc. (ABOS) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 4:00 PM EDT - 1 year ago

Acumen Pharmaceuticals to Report Second Quarter Results on August 13, 2024

Jul 29, 2024, 8:38 PM EDT - 1 year ago

Acumen Pharmaceuticals: Healthy Cash Runway And Market Potential In Alzheimer's

Jul 29, 2024, 7:00 AM EDT - 1 year ago

Acumen Pharmaceuticals Announces First Subject Dosed in Phase 1 Study of Subcutaneous Sabirnetug (ACU193) for Early Alzheimer's Disease

Jul 28, 2024, 7:30 AM EDT - 1 year ago

Acumen Pharmaceuticals Presents Patient Experience and Biomarker Data from Phase 1 INTERCEPT-AD Study at the Alzheimer's Association International Conference (AAIC®) 2024

May 14, 2024, 12:46 PM EDT - 1 year ago

Acumen Pharmaceuticals, Inc. (ABOS) Q1 2024 Earnings Call Transcript

May 14, 2024, 7:00 AM EDT - 1 year ago

Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights

May 13, 2024, 4:00 PM EDT - 1 year ago

Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

May 8, 2024, 5:47 PM EDT - 1 year ago

Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference

May 8, 2024, 8:00 AM EDT - 1 year ago

Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer's Disease

May 7, 2024, 4:00 PM EDT - 1 year ago

Acumen Pharmaceuticals to Report First Quarter Results on May 14, 2024

Apr 16, 2024, 8:00 AM EDT - 1 year ago

Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting

Apr 4, 2024, 8:00 AM EDT - 1 year ago

Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer's Disease

Mar 26, 2024, 10:45 AM EDT - 1 year ago

Acumen Pharmaceuticals, Inc. (ABOS) Q4 2023 Earnings Call Transcript

Mar 26, 2024, 7:00 AM EDT - 1 year ago

Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business Highlights

Mar 19, 2024, 4:00 PM EDT - 1 year ago

Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2023 Financial Results on March 26, 2024

Mar 12, 2024, 4:00 PM EDT - 1 year ago

Acumen Pharmaceuticals to Participate in the Stifel 2024 CNS Days

Mar 8, 2024, 8:50 AM EST - 1 year ago

Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer's at the AD/PD™ 2024 Annual Meeting

Feb 21, 2024, 8:00 AM EST - 1 year ago

Acumen Pharmaceuticals to Present Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer's at the AD/PD™ 2024 Annual Meeting

Feb 1, 2024, 7:00 AM EST - 2 years ago

Acumen Pharmaceuticals Appoints Dr. James Doherty as President and Chief Development Officer

Jan 4, 2024, 4:15 PM EST - 2 years ago

Acumen Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Nov 13, 2023, 4:29 PM EST - 2 years ago

Acumen Pharmaceuticals, Inc. (ABOS) Q3 2023 Earnings Call Transcript

Nov 13, 2023, 7:00 AM EST - 2 years ago

Acumen Pharmaceuticals Secures $50.0 Million Credit Facility with K2 HealthVentures

Nov 13, 2023, 7:00 AM EST - 2 years ago

Acumen Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Highlights

mhaven2020 Dec. 5 at 7:18 PM

$ABOS thanks for the dip. Bought more.

0 · Reply

SannieVerraderlijk Dec. 5 at 9:56 AM

$ABOS This is a sleeper, trading at 20ish million EV, huge indication and good scientific rationale. Could see runup into eoy 26

0 · Reply

mhaven2020 Dec. 4 at 6:08 PM

$ABOS 15 minute chart. Looking for direction. Needs volume.

0 · Reply

mhaven2020 Dec. 4 at 5:24 PM

$ABOS shouldn't be too long before these tickers start hitting market mover status. $IOVA . The number of times occurring in my daily scans is over the last 6 weeks.

1 · Reply

mhaven2020 Dec. 4 at 3:55 PM

$ABOS Just dropped a video on these two little gems. $IOVA Follow me on YouTube and X as well for more info. https://youtu.be/BVha65Bwzog

0 · Reply

mhaven2020 Dec. 3 at 5:36 PM

$ABOS steady...

0 · Reply

mhaven2020 Dec. 3 at 5:15 PM

$ABOS Seems to be gearing up for a run.

0 · Reply

mhaven2020 Dec. 3 at 2:28 PM

$ABOS $IOVA getting notes together for a video for youtube.

0 · Reply

mhaven2020 Dec. 3 at 2:17 PM

$ABOS heavy here. Something is coming.

0 · Reply

mhaven2020 Nov. 26 at 2:58 PM

$SAVA closed this and most of thenother ones. Still holding a bit of $IOVA and $IVVD. Dropping into $ABOS and $IVP for a few days with the profits.

1 · Reply

Stockley_Bulbousberries Nov. 25 at 7:13 PM

$ABOS

0 · Reply

SannieVerraderlijk Nov. 25 at 3:46 PM

$ABOS Starter

0 · Reply

RunnerSignals Nov. 19 at 7:11 PM

Wild upside vibes from $EKSO $OSTX $CATX $ABOS $LFMD today and charts look like they’re stretching before a sprint. Might be worth a peek before they decide where to run https://stocksrunner.com/news/2025-11-19-top-stock-upgrades-today-with-biggest-breakout-potential

0 · Reply

JarvisFlow Nov. 18 at 5:59 PM

B of A Securities updates rating for Acumen Pharmaceuticals ( $ABOS ) to Buy, target set at 9 → 8.

0 · Reply

prismmarketview Nov. 17 at 6:17 PM

(NASDAQ: $ABOS) Acumen dosed the first participant in the Phase 2 OLE of sabirnetug, its AβO-targeting antibody for early Alzheimer’s. Long-term safety & efficacy data expected ahead of topline ALTITUDE-AD results in late 2026. https://prismmarketview.com/acumen-pharmaceuticals-begins-dosing-in-phase-2-open-label-extension-study-of-sabirnetug-in-early-alzheimers-disease/

0 · Reply

DARKP00L Nov. 17 at 1:31 PM

$ABOS 08:13 on Nov. 17 2025 Acumen Pharmaceuticals Dosed First Patient In Phase 2 Open-Label Extension Study Of Sabirnetug In People with Early Alzheimer's. #tradeideas

0 · Reply